This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
EV-302
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO GU 2025
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2024
ASCO GU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
ASCO GU 2024 Prostate Cancer
Viewing 41-60 of 95 articles
ASCO GU 2024: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer Based on Site of Metastasis
ASCO GU 2024: Impact of a Rash Management Guide on Incidence and Severity of Rash with Apalutamide: Experience from the Apa-RP Study in High-Risk Localized Prostate Cancer
ASCO GU 2024: A Convolutional Neural Network Model Using Intraprostatic Patterns of 18F-DCFPyL Uptake in PSMA PET Images to Predict Synchronous Metastases
ASCO GU 2024: Relugolix Versus Leuprolide in Combination with Radiotherapy for Localized Prostate Cancer (REVELUTION Trial): An Initial Analysis of Patient Treatment Preferences and Quality of Life
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
ASCO GU 2024: NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-risk or High-risk Prostate Cancer with BRCA1/2 Gene Alterations
ASCO GU 2024: EMBARK Post Hoc Analysis of Sexual Activity Patient-Reported Outcome Measures
ASCO GU 2024: Clinical and Patient Factors Associated with Treatment Intensification for mHSPC
ASCO GU 2024: Multicentre Prospective Evaluation of Cognitive Function in Patients with Metastatic Castrate-Resistant Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide: The ACE Study
ASCO GU 2024: Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer
ASCO GU 2024: Stockholm3 Validation in a Multi-Ethnic Cohort for Prostate Cancer (SEPTA) Detection: A Multicentered, Prospective Trial
ASCO GU 2024: Preliminary Data from a Dose-escalation Phase 1 Study with HP518, an AR PROTAC Degrader: Safety, Tolerability, Pharmacokinetics, and First Assessment of Anti-tumor Activity in Patients with mCRPC
ASCO GU 2024: Survival and Fracture Risk with Radium-223 Therapy in mCRPC: A Real-World Analysis
ASCO GU 2024: Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life Extended DLL3-Targeting T-Cell Engager, in Patients with Neuroendocrine Prostate Cancer and Other Neuroendocrine Neoplasms
ASCO GU 2024: Real-world Analyses of Mortality Risk After ADT Initiation in Black vs White Patients with Prostate Cancer
ASCO GU 2024: Real-world Utilization Patterns of Radium-223 in Metastatic Prostate Cancer in the United States: An Administrative Claims Database Study
ASCO GU 2024: Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at Biochemical Recurrence to Predict Subsequent Biochemical Progression-Free Survival in Patients with Prostate Cancer
ASCO GU 2024: Daro-PET: A Phase 2 Trial of Darolutamide as a PSMA Expression Enhancer in Patients with Localized Prostate Cancer
ASCO GU 2024: Discussant: Androgen Deprivation & Radiation Therapy: Going Further, Together
ASCO GU 2024: Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free